绿叶制药:若欣林治疗广泛性焦虑障碍的中国Ⅲ期临床试验完成所有患者入组

格隆汇
Aug 18, 2025

格隆汇8月18日丨绿叶制药(02186.HK)宣布,集团自主研发的1类创新药若欣林(盐酸托鲁地文拉法辛缓释片)用于治疗广泛性焦虑障碍的Ⅲ期临床试验已完成所有患者入组。该项Ⅲ期临床试验为一项多中心、随机、双盲、安慰剂对照的研究,以评估若欣林治疗广泛性焦虑障碍的安全性和有效性。试验共纳入555例患者,主要终点为治疗第8周末汉密尔顿焦虑量表(HAM-A)评分总分较基线的变化.集团预计将于今年年底完成该项...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10